Ajinomoto reported net sales of approximately ¥1.42 trillion ($9.5 billion USD) for fiscal year 2024, up around 8% year over year. Growth was broad-based across its Seasoning & Foods and Healthcare & Life Sciences divisions, with the amino acid business — supplying pharmaceutical companies and semiconductor manufacturers — becoming an increasingly significant contributor to overall revenue.
Ajinomoto Revenue
Net sales in USD equivalent from 1960 through FY2024. JPY/USD at approximate annual averages. Ajinomoto's fiscal year ends in March. Revenue dip around FY2021 reflects the North American frozen food divestiture.
Ajinomoto Annual Revenue
| Fiscal Year | Revenue (USD equiv.) | YoY Change |
|---|---|---|
| FY2015 | $10.8B | — |
| FY2016 | $9.8B | −9.3% |
| FY2017 | $9.6B | −2.0% |
| FY2018 | $10.2B | +6.3% |
| FY2019 | $10.4B | +2.0% |
| FY2020 | $9.6B | −7.7% |
| FY2021 | $8.6B | −10.4% |
| FY2022 | $9.0B | +4.7% |
| FY2023 | $8.8B | −2.2% |
| FY2024 | $9.5B | +8.0% |
Note: Revenue figures converted from JPY at approximate annual average exchange rates. The FY2021 decline reflects the sale of Ajinomoto's North American frozen food operations. FY2016–FY2017 declines partially reflect JPY appreciation against the USD rather than underlying business contraction.